Technology Overview

Using antibody engineering technology, ITRI has developed "ITRI-501, an anti-TIGIT antibody drug," which effectively blocks TIGIT from binding to proteins on tumors, thereby activating T cell functions. Compared to clinical anti-TIGIT antibody drugs, ITRI-501 can significantly suppress tumor cell growth in mouse models. Additionally, preclinical trials have confirmed that ITRI-501 can be used as a monotherapy or combined with other drugs for treating solid tumors, underscoring its competitive market advantage.

Technical Superiority

1. ITRI-501 is non-immunogenic and targets a unique amino acid epitope on TIGIT.

2. It exhibits more vigorous ADCC cytotoxic activity against TIGIT-expressing regulatory T cells compared to competing anti-TIGIT antibodies.

3. Proven therapeutic efficacy as a monotherapy, effectively inhibiting colorectal tumor growth.

Application

1. Treatment of solid tumors

2. Cancer immunotherapy, with potential for combination therapy with other drugs